United States - English - NLM (National Library of Medicine)

exeltis usa, inc - vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), pyridoxine hydrochloride (unii: 68y4cf58bv) - vitamin a 2700 [iu] - vitafol ® -ob+dha is indicated to provide vitamin, mineral and omega-3 fatty acid supplementation prior to conception, throughout pregnancy, and during the postnatal period for the lactating and non-lactating mother.* vitafol ® -ob+dha does not contain fish, fish oils, fish proteins or fish byproducts. vitafol ® -ob+dha is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or to cyanocobalam

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium (unii: sy7q814vup) (calcium - unii:sy7q814vup), ferrous fumarate (unii: r5l488ry0q) (ferrous cation - unii:gw89581owr), magnesium (unii: i38zp9992a) (magnesium - unii:i38zp9992a), doconexent (unii: zad9okh9jc) (doconexent - unii:zad9okh9jc) - ascorbic acid 85 [iu] - description: pnv-dha is a prescription prenatal/postnatal multivitamin/mineral/essential fatty acid softgel. each softgel is blue in color, opaque and imprinted with “bp 321” on one side. other ingredients: bee’s wax, hydrogenated vegetable oil, lecithin, gelatin, glycerin, purified water, titanium dioxide, fd&c blue #1, fd&c red #3. indications: pnv-dha is a multivitamin/multimineral nutritional supplement indicated for use in the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation. contraindications: this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

puretek corporation - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 120 mg - pnv ob+dha is a multivitamin/mineral prescription drug indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. pnv ob+dha is contraindicated in patients with a known hypersensitivity  to any of the ingredients. pnv ob+dha is not indicated for pediatric or geriatric use.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - eicosapentaenoic acid; docosahexaenoic acid - oral capsule - 460mg ; 380mg

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), calcium (unii: sy7q814vup) (calcium - unii:sy7q814vup), ferrous fumarate (unii: r5l488ry0q) (ferrous cation - unii:gw89581owr), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), doconexent (unii: zad9okh9jc) (doconexent - unii:zad9okh9jc) - ascorbic acid 28 mg - pnv-dha + docusate is a prescription prenatal/postnatal multivitamin/multimineral softgel with dha. each softgel is red in color and imprinted with “323” on one side. † daily value (dv) not established. bovine gelatin, glycerin, soybean oil, soy lecithin, purified water, yellow beeswax, fd&c red # 40, titanium dioxide, orange cream flavor, ethyl vanillin, fd&c yellow # 6, and fd&c blue #1. contains soy. pnv-dha + docusate is a multivitamin/mineral prescription dietary supplement indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

city medical store abu dhabi-مدينة خليفة الصناعية 9 - linolenic acid, folic acid, betacon macomer, carnitine, iron, vitamin c, taurine, phosphorus, linoleic acid, magnesium, vitamin b1, betacon macomer, pantothenic acid, vitamin b2, galactose, vitamin b12, vitamin k, zinc, potassium, niacin, selenium, copper, calcium, sodium, chloride, vitamin a, inositol, iodine, docosahexaenoic acid, manganese, vitamin b6, choline, vitamin d3, vitamin e, biotin - liquid - combination - nutrition , blood-vitamins

United States - English - NLM (National Library of Medicine)

everett laboratories, inc. - vitamin a (unii: 81g40h8b0t) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), folic acid (unii: 935e97boy8) (folic aci - beta carotene 1100 [iu] - vitafol-one is indicated to provide vitamin, mineral, and omega-3 fatty acid supplementation prior to conception, throughout pregnancy, and during the postnatal period for the lactating and non-lactating mother, including individuals with known allergies to fish. vitafol-one does not contain fish, fish oils, fish proteins or fish byproducts. vitafol-one is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia, or cirrhosis of the liver. cyanocobalamin is contraindicated in patients with sensitivity to cobalt or

United States - English - NLM (National Library of Medicine)

puretek corporation - thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), niacin (unii: 2679mf687a) (niacin - unii:2679mf687a), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), ferrous fumarate (unii: r5l488ry0q) (ferrous c - thiamine 3 mg - prenatal + dha™ is indicated to provide vitamin/mineral and dha omega-3 fatty acid supplement to women throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. prenatal + dha™ may be beneficial in improving the nutritional status of women prior to conception. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -   usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -  

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - -  omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). -  usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters. -  laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. -  limitations of use: -  the